Insulet Corp
NASDAQ:PODD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
161.02
275.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Insulet Corp
Insulet Corp
Free Cash Flow
Insulet Corp
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Insulet Corp
NASDAQ:PODD
|
Free Cash Flow
$218.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Free Cash Flow
$3.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
11%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Free Cash Flow
$2.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
28%
|
CAGR 10-Years
10%
|
|
|
Stryker Corp
NYSE:SYK
|
Free Cash Flow
$3.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Free Cash Flow
$5.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Free Cash Flow
$586m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-1%
|
|
Insulet Corp
Glance View
Insulet Corporation is a pioneering medical device company, primarily recognized for its innovative Omnipod Insulin Management System, which revolutionizes diabetes care. Founded in 2000, Insulet has focused on developing patch pump technology that offers a seamless, tubeless insulin delivery solution for individuals with insulin-dependent diabetes. This cutting-edge product allows users to manage their insulin delivery discreetly and conveniently, enhancing their quality of life and simplifying the complex regimen of diabetes management. As the prevalence of diabetes continues to rise globally, Insulet stands at the forefront of meeting a substantial medical need, capturing a significant market share with its user-friendly technology. As an investor, understanding Insulet’s growth trajectory and market potential is essential. The company has witnessed consistent revenue growth, driven by increased adoption of its Omnipod systems, and has expanded its product portfolio to include a new generation of devices that offer even greater functionality. Insulet is also heavily investing in research and development to further innovate its offerings, positioning itself competitively in the fast-evolving diabetes care market. With strong industry partnerships and a commitment to enhancing user experience, Insulet represents not just a promising investment in healthcare technology but also a company that is fundamentally improving the lives of millions.
See Also
What is Insulet Corp's Free Cash Flow?
Free Cash Flow
218.2m
USD
Based on the financial report for Sep 30, 2024, Insulet Corp's Free Cash Flow amounts to 218.2m USD.
You don't have any saved screeners yet
